| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Genetic Testing | 15 | 2023 | 535 | 1.760 |
Why?
|
| Mutation | 29 | 2020 | 3968 | 1.330 |
Why?
|
| Exome | 6 | 2023 | 127 | 1.260 |
Why?
|
| Sequence Analysis, DNA | 9 | 2018 | 853 | 1.200 |
Why?
|
| DNA Mutational Analysis | 12 | 2015 | 526 | 1.030 |
Why?
|
| Genetic Predisposition to Disease | 14 | 2023 | 2271 | 0.870 |
Why?
|
| Glucuronosyltransferase | 14 | 2014 | 184 | 0.830 |
Why?
|
| Microcephaly | 5 | 2015 | 75 | 0.790 |
Why?
|
| Nerve Tissue Proteins | 3 | 2015 | 503 | 0.790 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 4 | 2015 | 379 | 0.790 |
Why?
|
| Genome, Human | 4 | 2021 | 756 | 0.750 |
Why?
|
| Genetic Variation | 14 | 2021 | 1351 | 0.740 |
Why?
|
| Germ-Line Mutation | 8 | 2023 | 329 | 0.740 |
Why?
|
| Intellectual Disability | 6 | 2018 | 186 | 0.720 |
Why?
|
| Cerebellar Ataxia | 2 | 2022 | 20 | 0.720 |
Why?
|
| Genetic Association Studies | 5 | 2017 | 294 | 0.700 |
Why?
|
| Laboratories | 4 | 2021 | 43 | 0.690 |
Why?
|
| Genotype | 25 | 2015 | 1851 | 0.670 |
Why?
|
| Ataxia | 1 | 2018 | 37 | 0.650 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 2013 | 315 | 0.650 |
Why?
|
| Phenotype | 16 | 2020 | 2378 | 0.630 |
Why?
|
| Exons | 8 | 2017 | 450 | 0.520 |
Why?
|
| Rett Syndrome | 2 | 2014 | 19 | 0.520 |
Why?
|
| Microtubule-Associated Proteins | 5 | 2009 | 176 | 0.500 |
Why?
|
| Child, Preschool | 17 | 2018 | 3612 | 0.500 |
Why?
|
| De Lange Syndrome | 4 | 2017 | 10 | 0.500 |
Why?
|
| Homeodomain Proteins | 3 | 2015 | 536 | 0.490 |
Why?
|
| Polymorphism, Genetic | 15 | 2012 | 819 | 0.490 |
Why?
|
| Humans | 92 | 2023 | 86643 | 0.490 |
Why?
|
| BRCA1 Protein | 4 | 2023 | 200 | 0.480 |
Why?
|
| Hematologic Neoplasms | 3 | 2023 | 329 | 0.480 |
Why?
|
| Nuclear Proteins | 6 | 2018 | 696 | 0.470 |
Why?
|
| Genetic Diseases, Inborn | 3 | 2011 | 101 | 0.470 |
Why?
|
| Epilepsy | 3 | 2013 | 397 | 0.470 |
Why?
|
| Heteroduplex Analysis | 1 | 2013 | 1 | 0.460 |
Why?
|
| Developmental Disabilities | 5 | 2013 | 195 | 0.450 |
Why?
|
| 1-Alkyl-2-acetylglycerophosphocholine Esterase | 4 | 2009 | 35 | 0.450 |
Why?
|
| Genomic Imprinting | 2 | 2004 | 33 | 0.430 |
Why?
|
| Genotyping Techniques | 1 | 2013 | 68 | 0.430 |
Why?
|
| Classical Lissencephalies and Subcortical Band Heterotopias | 2 | 2009 | 13 | 0.430 |
Why?
|
| Myopathies, Structural, Congenital | 3 | 2012 | 9 | 0.430 |
Why?
|
| Child | 21 | 2018 | 6927 | 0.410 |
Why?
|
| Transcription Factors | 5 | 2015 | 1565 | 0.400 |
Why?
|
| Neuropeptides | 3 | 2008 | 112 | 0.400 |
Why?
|
| Camptothecin | 6 | 2014 | 189 | 0.390 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2011 | 49 | 0.390 |
Why?
|
| Rare Diseases | 2 | 2008 | 59 | 0.380 |
Why?
|
| Vestibular Diseases | 2 | 2022 | 27 | 0.380 |
Why?
|
| Female | 49 | 2023 | 44532 | 0.380 |
Why?
|
| Gene Duplication | 3 | 2017 | 125 | 0.380 |
Why?
|
| Hematologic Diseases | 2 | 2022 | 79 | 0.370 |
Why?
|
| Forkhead Transcription Factors | 1 | 2011 | 166 | 0.360 |
Why?
|
| Gene Frequency | 5 | 2015 | 677 | 0.360 |
Why?
|
| Genetic Research | 2 | 2014 | 17 | 0.360 |
Why?
|
| Anemia, Aplastic | 2 | 2021 | 30 | 0.350 |
Why?
|
| High-Throughput Nucleotide Sequencing | 6 | 2023 | 456 | 0.340 |
Why?
|
| Male | 43 | 2023 | 40965 | 0.330 |
Why?
|
| Growth Disorders | 2 | 2005 | 63 | 0.330 |
Why?
|
| Genetic Services | 1 | 2008 | 7 | 0.330 |
Why?
|
| Cell Cycle Proteins | 5 | 2015 | 388 | 0.330 |
Why?
|
| Models, Organizational | 1 | 2008 | 46 | 0.320 |
Why?
|
| Gene Deletion | 2 | 2008 | 329 | 0.320 |
Why?
|
| Infant | 14 | 2018 | 3046 | 0.320 |
Why?
|
| Genome | 1 | 2011 | 372 | 0.320 |
Why?
|
| BRCA2 Protein | 3 | 2023 | 158 | 0.320 |
Why?
|
| Neurodegenerative Diseases | 2 | 2022 | 44 | 0.310 |
Why?
|
| Promoter Regions, Genetic | 9 | 2015 | 937 | 0.300 |
Why?
|
| Antineoplastic Agents, Phytogenic | 4 | 2014 | 276 | 0.300 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 6 | 2007 | 375 | 0.290 |
Why?
|
| Sequence Deletion | 4 | 2017 | 205 | 0.280 |
Why?
|
| DNA | 3 | 2013 | 1294 | 0.280 |
Why?
|
| Base Sequence | 10 | 2017 | 2330 | 0.280 |
Why?
|
| Heterozygote | 6 | 2018 | 365 | 0.280 |
Why?
|
| Phosphoric Monoester Hydrolases | 2 | 2012 | 51 | 0.280 |
Why?
|
| Genetics, Medical | 2 | 2021 | 52 | 0.270 |
Why?
|
| Chromosomes, Human, Pair 6 | 2 | 2008 | 125 | 0.260 |
Why?
|
| Diabetes Mellitus | 3 | 2016 | 806 | 0.260 |
Why?
|
| Aneuploidy | 2 | 2005 | 55 | 0.260 |
Why?
|
| Pharmacogenetics | 4 | 2014 | 434 | 0.250 |
Why?
|
| Endometrial Neoplasms | 2 | 2004 | 193 | 0.250 |
Why?
|
| Neoplasms | 5 | 2023 | 2898 | 0.250 |
Why?
|
| Genetic Counseling | 3 | 2014 | 100 | 0.250 |
Why?
|
| Prader-Willi Syndrome | 1 | 2004 | 8 | 0.240 |
Why?
|
| Tumor Suppressor Proteins | 2 | 2012 | 279 | 0.240 |
Why?
|
| Angelman Syndrome | 1 | 2004 | 7 | 0.240 |
Why?
|
| Molecular Sequence Data | 10 | 2015 | 3030 | 0.240 |
Why?
|
| Polymorphism, Single Nucleotide | 7 | 2014 | 2357 | 0.230 |
Why?
|
| Biomarkers | 3 | 2021 | 1718 | 0.230 |
Why?
|
| Bilateral Vestibulopathy | 1 | 2022 | 3 | 0.220 |
Why?
|
| Methyl-CpG-Binding Protein 2 | 2 | 2014 | 16 | 0.220 |
Why?
|
| Genetic Diseases, X-Linked | 2 | 2015 | 34 | 0.220 |
Why?
|
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2022 | 10 | 0.220 |
Why?
|
| Genetic Linkage | 3 | 2008 | 623 | 0.220 |
Why?
|
| Chromosomal Proteins, Non-Histone | 2 | 2015 | 58 | 0.210 |
Why?
|
| Protein Tyrosine Phosphatases | 1 | 2002 | 46 | 0.210 |
Why?
|
| Adult | 21 | 2023 | 25648 | 0.210 |
Why?
|
| DNA Helicases | 2 | 2023 | 79 | 0.210 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2022 | 85 | 0.210 |
Why?
|
| Databases, Genetic | 3 | 2018 | 260 | 0.200 |
Why?
|
| X Chromosome | 1 | 2002 | 152 | 0.200 |
Why?
|
| Carcinoma | 1 | 2004 | 436 | 0.200 |
Why?
|
| Macroglossia | 1 | 2000 | 2 | 0.200 |
Why?
|
| Pilot Projects | 2 | 2021 | 839 | 0.200 |
Why?
|
| Receptors, Colony-Stimulating Factor | 1 | 2020 | 5 | 0.190 |
Why?
|
| Craniofacial Abnormalities | 1 | 2000 | 36 | 0.190 |
Why?
|
| Graft vs Host Disease | 1 | 2023 | 365 | 0.190 |
Why?
|
| Hematology | 1 | 2020 | 29 | 0.190 |
Why?
|
| Lymphoma | 1 | 2022 | 262 | 0.190 |
Why?
|
| Telomerase | 1 | 2020 | 55 | 0.190 |
Why?
|
| Syndrome | 6 | 2022 | 446 | 0.190 |
Why?
|
| B7-H1 Antigen | 1 | 2022 | 250 | 0.190 |
Why?
|
| Adolescent | 10 | 2021 | 8981 | 0.180 |
Why?
|
| Mesothelioma | 1 | 2023 | 311 | 0.180 |
Why?
|
| Gene Expression Profiling | 2 | 2005 | 1384 | 0.180 |
Why?
|
| DNA Methylation | 5 | 2016 | 628 | 0.180 |
Why?
|
| Cohort Studies | 6 | 2015 | 2767 | 0.180 |
Why?
|
| Canada | 2 | 2018 | 204 | 0.180 |
Why?
|
| Multiplex Polymerase Chain Reaction | 2 | 2016 | 33 | 0.170 |
Why?
|
| Facies | 4 | 2017 | 27 | 0.170 |
Why?
|
| Adenosine Monophosphate | 1 | 2018 | 27 | 0.170 |
Why?
|
| Pedigree | 5 | 2013 | 966 | 0.170 |
Why?
|
| Axon Guidance | 1 | 2018 | 5 | 0.170 |
Why?
|
| Aged, 80 and over | 8 | 2021 | 6509 | 0.170 |
Why?
|
| Comparative Genomic Hybridization | 3 | 2017 | 39 | 0.170 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2021 | 381 | 0.170 |
Why?
|
| Congenital Hyperinsulinism | 1 | 2018 | 13 | 0.160 |
Why?
|
| Histone Demethylases | 1 | 2018 | 30 | 0.160 |
Why?
|
| Zinc | 1 | 2018 | 91 | 0.160 |
Why?
|
| Hemoglobinuria, Paroxysmal | 1 | 2018 | 5 | 0.160 |
Why?
|
| Conserved Sequence | 1 | 2018 | 210 | 0.160 |
Why?
|
| DNA-Binding Proteins | 3 | 2018 | 1208 | 0.160 |
Why?
|
| Abnormalities, Multiple | 2 | 2018 | 232 | 0.160 |
Why?
|
| Bone Marrow Diseases | 1 | 2018 | 40 | 0.160 |
Why?
|
| Middle Aged | 15 | 2023 | 25028 | 0.160 |
Why?
|
| Face | 1 | 2018 | 114 | 0.150 |
Why?
|
| Histone Deacetylases | 1 | 2017 | 63 | 0.150 |
Why?
|
| Clinical Laboratory Information Systems | 1 | 2017 | 1 | 0.150 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2021 | 346 | 0.150 |
Why?
|
| Germ Cells | 3 | 2023 | 126 | 0.150 |
Why?
|
| Liver | 3 | 2014 | 1230 | 0.150 |
Why?
|
| Microfilament Proteins | 1 | 2018 | 208 | 0.150 |
Why?
|
| Disclosure | 2 | 2016 | 108 | 0.150 |
Why?
|
| Aged | 11 | 2021 | 18415 | 0.150 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2017 | 73 | 0.150 |
Why?
|
| Alleles | 6 | 2020 | 1128 | 0.150 |
Why?
|
| Leukemia, Myeloid | 1 | 2018 | 249 | 0.140 |
Why?
|
| RNA, Messenger | 5 | 2015 | 1981 | 0.140 |
Why?
|
| Cell Movement | 2 | 2018 | 758 | 0.140 |
Why?
|
| Neutropenia | 2 | 2009 | 215 | 0.140 |
Why?
|
| Young Adult | 5 | 2021 | 5976 | 0.140 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 1 | 2023 | 878 | 0.140 |
Why?
|
| Genomics | 4 | 2023 | 720 | 0.140 |
Why?
|
| Mutation, Missense | 4 | 2015 | 276 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2016 | 69 | 0.140 |
Why?
|
| Neoplasm Proteins | 2 | 2018 | 532 | 0.140 |
Why?
|
| Mosaicism | 3 | 2009 | 67 | 0.140 |
Why?
|
| Reference Standards | 2 | 2014 | 159 | 0.140 |
Why?
|
| Dynamin II | 2 | 2012 | 15 | 0.130 |
Why?
|
| Spasms, Infantile | 1 | 2015 | 30 | 0.130 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2016 | 111 | 0.130 |
Why?
|
| Arginine-tRNA Ligase | 1 | 2015 | 3 | 0.130 |
Why?
|
| Failure to Thrive | 1 | 2015 | 17 | 0.130 |
Why?
|
| Language Development Disorders | 1 | 2015 | 24 | 0.130 |
Why?
|
| Chondroitin Sulfate Proteoglycans | 1 | 2015 | 38 | 0.130 |
Why?
|
| Lissencephaly | 2 | 2018 | 22 | 0.130 |
Why?
|
| Prognosis | 6 | 2021 | 3679 | 0.130 |
Why?
|
| Repressor Proteins | 1 | 2017 | 403 | 0.130 |
Why?
|
| Pantothenate Kinase-Associated Neurodegeneration | 2 | 2005 | 3 | 0.130 |
Why?
|
| Bilirubin | 4 | 2009 | 125 | 0.120 |
Why?
|
| Patient Education as Topic | 2 | 2014 | 351 | 0.120 |
Why?
|
| Microsatellite Repeats | 3 | 2004 | 145 | 0.120 |
Why?
|
| Infant, Newborn | 5 | 2016 | 2379 | 0.120 |
Why?
|
| Fathers | 2 | 2008 | 70 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2014 | 65 | 0.120 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 2 | 2005 | 80 | 0.120 |
Why?
|
| Genes, BRCA1 | 2 | 2005 | 192 | 0.120 |
Why?
|
| Program Development | 1 | 2014 | 124 | 0.120 |
Why?
|
| Endosomal Sorting Complexes Required for Transport | 1 | 2013 | 15 | 0.110 |
Why?
|
| Cystic Fibrosis | 1 | 2014 | 112 | 0.110 |
Why?
|
| Transcription, Genetic | 3 | 2014 | 1135 | 0.110 |
Why?
|
| Seizures | 2 | 2013 | 297 | 0.110 |
Why?
|
| Nucleic Acid Denaturation | 1 | 2013 | 34 | 0.110 |
Why?
|
| Quality Assurance, Health Care | 2 | 2012 | 220 | 0.110 |
Why?
|
| Carbidopa | 1 | 2012 | 5 | 0.110 |
Why?
|
| Retrospective Studies | 5 | 2022 | 8489 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 1464 | 0.110 |
Why?
|
| Corpus Callosum | 2 | 2011 | 56 | 0.110 |
Why?
|
| Ubiquitin Thiolesterase | 1 | 2013 | 63 | 0.110 |
Why?
|
| Capillaries | 1 | 2013 | 91 | 0.110 |
Why?
|
| Choristoma | 2 | 2003 | 68 | 0.110 |
Why?
|
| Levodopa | 1 | 2012 | 36 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 2014 | 181 | 0.110 |
Why?
|
| Phosphoproteins | 1 | 2013 | 254 | 0.110 |
Why?
|
| Introns | 5 | 2007 | 289 | 0.110 |
Why?
|
| Consensus | 1 | 2014 | 335 | 0.110 |
Why?
|
| Age of Onset | 1 | 2013 | 310 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2013 | 3362 | 0.110 |
Why?
|
| Genes, Dominant | 1 | 2012 | 117 | 0.110 |
Why?
|
| Polymerase Chain Reaction | 4 | 2016 | 927 | 0.110 |
Why?
|
| Methylenetetrahydrofolate Reductase (NADPH2) | 2 | 2009 | 26 | 0.100 |
Why?
|
| Guanylate Kinases | 1 | 2011 | 12 | 0.100 |
Why?
|
| Gene Expression Regulation, Enzymologic | 3 | 2008 | 214 | 0.100 |
Why?
|
| Group VI Phospholipases A2 | 1 | 2011 | 1 | 0.100 |
Why?
|
| Electroencephalography | 2 | 2013 | 709 | 0.100 |
Why?
|
| Dyskinesias | 1 | 2011 | 7 | 0.100 |
Why?
|
| Hypoglycemic Agents | 1 | 2014 | 378 | 0.100 |
Why?
|
| United States | 7 | 2021 | 6672 | 0.100 |
Why?
|
| Academic Medical Centers | 1 | 2014 | 379 | 0.100 |
Why?
|
| Skin Diseases | 1 | 2013 | 166 | 0.100 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 1920 | 0.100 |
Why?
|
| Molecular Typing | 1 | 2011 | 17 | 0.100 |
Why?
|
| Synaptic Membranes | 1 | 2011 | 14 | 0.100 |
Why?
|
| Neurons | 2 | 2018 | 1546 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2011 | 59 | 0.100 |
Why?
|
| Nervous System Malformations | 2 | 2018 | 46 | 0.100 |
Why?
|
| Oxidoreductases | 1 | 2011 | 112 | 0.090 |
Why?
|
| Glutathione Transferase | 3 | 2005 | 111 | 0.090 |
Why?
|
| alpha 1-Antitrypsin | 1 | 2009 | 16 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2009 | 21 | 0.090 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2014 | 508 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 2 | 2016 | 1036 | 0.090 |
Why?
|
| Chromosome Mapping | 1 | 2012 | 1074 | 0.090 |
Why?
|
| Receptors, Calcitriol | 3 | 2005 | 129 | 0.090 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2023 | 302 | 0.090 |
Why?
|
| Point Mutation | 2 | 2015 | 246 | 0.080 |
Why?
|
| Insulin | 1 | 2014 | 1160 | 0.080 |
Why?
|
| Warfarin | 1 | 2009 | 103 | 0.080 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2020 | 348 | 0.080 |
Why?
|
| Brain | 3 | 2011 | 2216 | 0.080 |
Why?
|
| Telomere | 2 | 2020 | 108 | 0.080 |
Why?
|
| Membrane Glycoproteins | 1 | 2011 | 428 | 0.080 |
Why?
|
| Protein Tyrosine Phosphatases, Non-Receptor | 2 | 2012 | 6 | 0.080 |
Why?
|
| Daunorubicin | 1 | 2008 | 78 | 0.080 |
Why?
|
| Genes | 1 | 2008 | 305 | 0.080 |
Why?
|
| Certification | 1 | 2008 | 58 | 0.080 |
Why?
|
| Breast Neoplasms | 3 | 2007 | 2903 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 2 | 2005 | 154 | 0.080 |
Why?
|
| Fetal Growth Retardation | 1 | 2008 | 66 | 0.080 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 44 | 0.080 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 879 | 0.080 |
Why?
|
| Haplotypes | 5 | 2008 | 642 | 0.080 |
Why?
|
| Topoisomerase I Inhibitors | 2 | 2004 | 33 | 0.080 |
Why?
|
| Chromosome Deletion | 1 | 2008 | 229 | 0.070 |
Why?
|
| Research Design | 2 | 2008 | 594 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2008 | 592 | 0.070 |
Why?
|
| Hearing Loss | 1 | 2007 | 56 | 0.070 |
Why?
|
| Methotrexate | 2 | 2007 | 249 | 0.070 |
Why?
|
| Information Dissemination | 2 | 2017 | 103 | 0.070 |
Why?
|
| Anticoagulants | 1 | 2009 | 408 | 0.070 |
Why?
|
| Case-Control Studies | 3 | 2016 | 1805 | 0.070 |
Why?
|
| Tonic Pupil | 1 | 2005 | 1 | 0.070 |
Why?
|
| Uniparental Disomy | 1 | 2005 | 5 | 0.070 |
Why?
|
| Connexins | 1 | 2007 | 200 | 0.070 |
Why?
|
| Dwarfism | 1 | 2005 | 16 | 0.070 |
Why?
|
| Ocular Motility Disorders | 1 | 2005 | 17 | 0.070 |
Why?
|
| Trisomy | 1 | 2005 | 55 | 0.070 |
Why?
|
| Retinal Degeneration | 1 | 2005 | 28 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2005 | 110 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 7 | 1 | 2005 | 79 | 0.070 |
Why?
|
| Severity of Illness Index | 2 | 2008 | 1801 | 0.070 |
Why?
|
| Fetal Diseases | 1 | 2005 | 81 | 0.070 |
Why?
|
| Molecular Biology | 1 | 2005 | 89 | 0.060 |
Why?
|
| DNA Copy Number Variations | 2 | 2017 | 171 | 0.060 |
Why?
|
| Osteonecrosis | 1 | 2004 | 21 | 0.060 |
Why?
|
| Hip | 1 | 2004 | 18 | 0.060 |
Why?
|
| X Chromosome Inactivation | 2 | 2017 | 28 | 0.060 |
Why?
|
| Joint Diseases | 1 | 2004 | 49 | 0.060 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2004 | 157 | 0.060 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2004 | 128 | 0.060 |
Why?
|
| Hyperhomocysteinemia | 1 | 2003 | 11 | 0.060 |
Why?
|
| Carboxylesterase | 1 | 2003 | 10 | 0.060 |
Why?
|
| Oxidoreductases Acting on CH-NH Group Donors | 1 | 2003 | 19 | 0.060 |
Why?
|
| Homocysteine | 1 | 2003 | 29 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2004 | 120 | 0.060 |
Why?
|
| Siblings | 2 | 2015 | 111 | 0.060 |
Why?
|
| Etoposide | 1 | 2003 | 196 | 0.060 |
Why?
|
| North America | 1 | 2023 | 180 | 0.060 |
Why?
|
| Australia | 1 | 2023 | 99 | 0.060 |
Why?
|
| Dystonia | 1 | 2003 | 29 | 0.060 |
Why?
|
| Microsomes, Liver | 1 | 2002 | 49 | 0.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2005 | 1197 | 0.060 |
Why?
|
| Prednisone | 1 | 2003 | 258 | 0.060 |
Why?
|
| Glucuronides | 3 | 2009 | 34 | 0.060 |
Why?
|
| Carrier Proteins | 2 | 2003 | 673 | 0.050 |
Why?
|
| Cyclophosphamide | 1 | 2023 | 299 | 0.050 |
Why?
|
| Morphine | 1 | 2003 | 130 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2003 | 166 | 0.050 |
Why?
|
| Brain Diseases | 1 | 2003 | 180 | 0.050 |
Why?
|
| Brain Neoplasms | 1 | 2007 | 763 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2021 | 3640 | 0.050 |
Why?
|
| Cell Line | 3 | 2014 | 2468 | 0.050 |
Why?
|
| Colorectal Neoplasms | 1 | 2009 | 938 | 0.050 |
Why?
|
| Ligands | 1 | 2022 | 433 | 0.050 |
Why?
|
| Survival Analysis | 1 | 2004 | 1538 | 0.050 |
Why?
|
| Biology | 1 | 2020 | 50 | 0.050 |
Why?
|
| Frameshift Mutation | 2 | 2013 | 51 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2002 | 319 | 0.050 |
Why?
|
| Linkage Disequilibrium | 3 | 2007 | 473 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2022 | 751 | 0.050 |
Why?
|
| ErbB Receptors | 1 | 2003 | 485 | 0.050 |
Why?
|
| Risk | 3 | 2007 | 674 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2004 | 1565 | 0.040 |
Why?
|
| Amino Acid Sequence | 3 | 2012 | 2062 | 0.040 |
Why?
|
| Multivariate Analysis | 3 | 2009 | 999 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2004 | 1991 | 0.040 |
Why?
|
| Fibroblasts | 1 | 2022 | 729 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2000 | 207 | 0.040 |
Why?
|
| Cilia | 1 | 2018 | 29 | 0.040 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 2 | 2009 | 44 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2003 | 413 | 0.040 |
Why?
|
| Cerebral Cortex | 1 | 2002 | 584 | 0.040 |
Why?
|
| Recombination, Genetic | 1 | 2000 | 439 | 0.040 |
Why?
|
| Microtubules | 1 | 2018 | 119 | 0.040 |
Why?
|
| Pathology, Molecular | 1 | 2018 | 34 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2011 | 207 | 0.040 |
Why?
|
| Chromosome Breakpoints | 1 | 2017 | 15 | 0.040 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2002 | 645 | 0.040 |
Why?
|
| Brain Stem | 1 | 2018 | 165 | 0.040 |
Why?
|
| Telomere Shortening | 1 | 2018 | 23 | 0.040 |
Why?
|
| Biotransformation | 2 | 2009 | 50 | 0.040 |
Why?
|
| Gene Expression | 2 | 2015 | 1284 | 0.040 |
Why?
|
| Prevalence | 1 | 2020 | 1239 | 0.040 |
Why?
|
| Morphine Derivatives | 2 | 2008 | 8 | 0.040 |
Why?
|
| Research Report | 1 | 2016 | 44 | 0.040 |
Why?
|
| Sample Size | 1 | 2016 | 130 | 0.040 |
Why?
|
| Incidental Findings | 1 | 2016 | 95 | 0.030 |
Why?
|
| Homozygote | 2 | 2007 | 200 | 0.030 |
Why?
|
| Prospective Studies | 3 | 2016 | 4213 | 0.030 |
Why?
|
| Cytochrome P-450 Enzyme System | 2 | 2008 | 79 | 0.030 |
Why?
|
| Cell Line, Tumor | 3 | 2008 | 2426 | 0.030 |
Why?
|
| Codon, Initiator | 1 | 2015 | 21 | 0.030 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2015 | 18 | 0.030 |
Why?
|
| Cerebellar Diseases | 1 | 2015 | 20 | 0.030 |
Why?
|
| Peroxisome-Targeting Signal 1 Receptor | 1 | 2014 | 3 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 2014 | 60 | 0.030 |
Why?
|
| Remission Induction | 2 | 2007 | 722 | 0.030 |
Why?
|
| India | 1 | 2014 | 120 | 0.030 |
Why?
|
| Hirsutism | 1 | 2013 | 61 | 0.030 |
Why?
|
| Founder Effect | 1 | 2014 | 104 | 0.030 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 122 | 0.030 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 416 | 0.030 |
Why?
|
| Animals | 2 | 2011 | 26582 | 0.030 |
Why?
|
| HEK293 Cells | 1 | 2015 | 615 | 0.030 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2013 | 68 | 0.030 |
Why?
|
| Genes, Recessive | 1 | 2013 | 87 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2015 | 678 | 0.030 |
Why?
|
| Patient Compliance | 1 | 2014 | 227 | 0.030 |
Why?
|
| Lymphocytes | 2 | 2005 | 464 | 0.030 |
Why?
|
| Software | 1 | 2017 | 654 | 0.030 |
Why?
|
| Risk Factors | 3 | 2009 | 5417 | 0.030 |
Why?
|
| Ryanodine Receptor Calcium Release Channel | 1 | 2012 | 23 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2012 | 224 | 0.030 |
Why?
|
| Karyotyping | 1 | 2011 | 250 | 0.030 |
Why?
|
| Sequence Alignment | 1 | 2012 | 351 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2013 | 547 | 0.020 |
Why?
|
| Neuroimaging | 1 | 2011 | 113 | 0.020 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2011 | 273 | 0.020 |
Why?
|
| Treatment Outcome | 3 | 2009 | 7993 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 1961 | 0.020 |
Why?
|
| Vitamin K Epoxide Reductases | 1 | 2009 | 16 | 0.020 |
Why?
|
| Cytochrome P-450 CYP2C9 | 1 | 2009 | 21 | 0.020 |
Why?
|
| Chicago | 1 | 2014 | 1379 | 0.020 |
Why?
|
| Multidrug Resistance-Associated Proteins | 1 | 2009 | 27 | 0.020 |
Why?
|
| Organic Anion Transporters | 1 | 2009 | 27 | 0.020 |
Why?
|
| Mixed Function Oxygenases | 1 | 2009 | 68 | 0.020 |
Why?
|
| Hepatocyte Nuclear Factor 1-alpha | 1 | 2009 | 80 | 0.020 |
Why?
|
| Epirubicin | 1 | 2008 | 14 | 0.020 |
Why?
|
| Models, Biological | 2 | 2007 | 1749 | 0.020 |
Why?
|
| United States Food and Drug Administration | 1 | 2009 | 127 | 0.020 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2008 | 9 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2016 | 2501 | 0.020 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2008 | 64 | 0.020 |
Why?
|
| Cytogenetic Analysis | 1 | 2008 | 71 | 0.020 |
Why?
|
| Hepatoblastoma | 1 | 2007 | 12 | 0.020 |
Why?
|
| Luciferases, Firefly | 1 | 2007 | 12 | 0.020 |
Why?
|
| Chromosome Disorders | 1 | 2008 | 114 | 0.020 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2008 | 70 | 0.020 |
Why?
|
| Connexin 30 | 1 | 2007 | 1 | 0.020 |
Why?
|
| Connexin 26 | 1 | 2007 | 17 | 0.020 |
Why?
|
| Medulloblastoma | 1 | 2007 | 36 | 0.020 |
Why?
|
| Africa | 1 | 2007 | 98 | 0.020 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2008 | 114 | 0.020 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 13 | 0.020 |
Why?
|
| Mycophenolic Acid | 1 | 2007 | 87 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2009 | 916 | 0.020 |
Why?
|
| Flavonoids | 1 | 2007 | 85 | 0.020 |
Why?
|
| Alternative Splicing | 1 | 2008 | 201 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2008 | 596 | 0.020 |
Why?
|
| Genes, Reporter | 1 | 2007 | 268 | 0.020 |
Why?
|
| Pregnancy | 2 | 2005 | 2894 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2008 | 162 | 0.020 |
Why?
|
| Substrate Specificity | 1 | 2007 | 347 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2008 | 217 | 0.020 |
Why?
|
| Sex Factors | 1 | 2009 | 1054 | 0.020 |
Why?
|
| Piperidines | 1 | 2007 | 181 | 0.020 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2005 | 9 | 0.020 |
Why?
|
| Hydroxamic Acids | 1 | 2005 | 49 | 0.020 |
Why?
|
| Transfection | 1 | 2007 | 896 | 0.020 |
Why?
|
| Zinc Fingers | 1 | 2005 | 56 | 0.020 |
Why?
|
| Quality Control | 1 | 2005 | 117 | 0.020 |
Why?
|
| Electroretinography | 1 | 2005 | 76 | 0.020 |
Why?
|
| Thymidylate Synthase | 1 | 2005 | 13 | 0.020 |
Why?
|
| Patient Selection | 1 | 2009 | 685 | 0.020 |
Why?
|
| Azacitidine | 1 | 2005 | 137 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 5 | 1 | 2005 | 109 | 0.020 |
Why?
|
| Prenatal Diagnosis | 1 | 2005 | 104 | 0.020 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2007 | 199 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2007 | 2360 | 0.020 |
Why?
|
| Sex Chromosome Disorders | 1 | 2004 | 2 | 0.020 |
Why?
|
| Agenesis of Corpus Callosum | 1 | 2004 | 25 | 0.020 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2005 | 236 | 0.020 |
Why?
|
| Genitalia, Male | 1 | 2004 | 24 | 0.020 |
Why?
|
| Genitalia, Female | 1 | 2004 | 25 | 0.020 |
Why?
|
| Proteins | 1 | 2009 | 777 | 0.020 |
Why?
|
| Genes, MDR | 1 | 2003 | 7 | 0.010 |
Why?
|
| Reduced Folate Carrier Protein | 1 | 2003 | 2 | 0.010 |
Why?
|
| Glutathione S-Transferase pi | 1 | 2003 | 18 | 0.010 |
Why?
|
| Longitudinal Studies | 1 | 2007 | 1019 | 0.010 |
Why?
|
| Breast | 1 | 2005 | 288 | 0.010 |
Why?
|
| Cytochrome P-450 CYP3A | 1 | 2003 | 43 | 0.010 |
Why?
|
| Dosage Compensation, Genetic | 1 | 2003 | 17 | 0.010 |
Why?
|
| Analgesia, Patient-Controlled | 1 | 2003 | 16 | 0.010 |
Why?
|
| Transcription Initiation Site | 1 | 2003 | 45 | 0.010 |
Why?
|
| 5' Untranslated Regions | 1 | 2003 | 49 | 0.010 |
Why?
|
| Chromosomes, Human, Pair 16 | 1 | 2003 | 79 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2003 | 72 | 0.010 |
Why?
|
| Quantitative Trait Loci | 1 | 2007 | 576 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 290 | 0.010 |
Why?
|
| Phenobarbital | 1 | 2002 | 33 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2009 | 2705 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2005 | 689 | 0.010 |
Why?
|
| Isoenzymes | 1 | 2003 | 271 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 265 | 0.010 |
Why?
|
| Cell Division | 1 | 2004 | 696 | 0.010 |
Why?
|
| Base Pair Mismatch | 1 | 2002 | 27 | 0.010 |
Why?
|
| Disease-Free Survival | 1 | 2005 | 1204 | 0.010 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2002 | 33 | 0.010 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2002 | 30 | 0.010 |
Why?
|
| Recurrence | 1 | 2005 | 1139 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 303 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2009 | 2261 | 0.010 |
Why?
|
| Neuropsychological Tests | 1 | 2003 | 502 | 0.010 |
Why?
|
| Binding Sites | 1 | 2003 | 1098 | 0.010 |
Why?
|
| Computational Biology | 1 | 2003 | 528 | 0.010 |
Why?
|
| Age Factors | 1 | 2004 | 1851 | 0.010 |
Why?
|
| DNA Repair | 1 | 2002 | 356 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2002 | 579 | 0.010 |
Why?
|
| Disease Progression | 1 | 2004 | 1531 | 0.010 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2003 | 384 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2004 | 2818 | 0.010 |
Why?
|
| Survival Rate | 1 | 2002 | 1863 | 0.010 |
Why?
|
| Time Factors | 1 | 2005 | 5210 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2002 | 2232 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 2438 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2003 | 3241 | 0.010 |
Why?
|